CLAIMS

1. A compound represented by the formula (I)



(I)

wherein R stands for a lower alkyl group optionally substituted by hydroxyl group which may be substituted, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R_1 stands for a lower alkyl group and W stands for a halogen atom, or a salt thereof.

2. The compound as claimed in claim 1, wherein R is C_{1-6} alkyl which may have 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy.

3. The compound as claimed in claim 1, wherein R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy.

4. The compound as claimed in claim 1, wherein R is 2,2-dimethyl-3-hydroxypropyl, 3-hydroxy-2-hydroxymethyl-2-methylpropyl, 3-acetoxy-2,2-dimethylpropyl, 3-acetoxy-2-hydroxymethyl-2-methylpropyl or 3-acetoxy-2-acetoxymethyl-2-methylpropyl.

5. The compound as claimed in claim 1, wherein R_1 is methyl.

6. The compound as claimed in claim 1, wherein W is

chlorine atom.

7. The compound as claimed in claim 1, wherein X is a carbamoyl group represented by the formula



wherein R_2 and R_3 are independently

(i) hydrogen,

(ii) optionally substituted hydrocarbon group,

(iii) optionally substituted heterocyclic group, or

(iv) acyl group

or R_2 and R_3 may form an optionally substituted 5 to 6 membered ring together with the adjacent nitrogen atom, said ring may contain 1 to 4 hetero atoms selected from nitrogen, oxygen and sulfur in addition to said nitrogen atom.

8. The compound as claimed in claim 7, wherein R_2 is hydrogen or C_{1-7} alkyl, R_3 is

(1) a hydrocarbon group selected from the group consisting of

(a) C_{1-7} alkyl,

(b) C_{3-7} cycloalkyl,

(c) C_{2-6} alkenyl,

(d) C_{6-10} aryl and

(e) C_{6-10} aryl-C_{1-4} alkyl,

wherein each of said groups (a), (b) and (c) may have 1 to 4 substituents selected from the group consisting of

(i) carboxyl which may be esterified with C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(ii) phosphono group which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyloxy-C_{1-6} alkyl,

(iii) sulfo group,

(iv) sulfonamido which may be substituted by C_{1-6}

alkyl or C_{6-10} aryl-C_{1-4} alkyl,
(v) hydroxyl group which may be alkylated with C_{1-3} alkyl,
(vi) sulfhydryl group which may be alkylated with C_{1-3} alkyl,
(vii) carbamoyl,
(viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, chlorine, fluorine, aminosulfonyl and amino which may be mono or di-substituted by C_{1-3} alkyl,
(ix) amino which may be mono- or di-substituted by C_{1-3} alkyl,
(x) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl, 4-phenylpiperazinyl, 1,2,3,4-tetrahydroisoquinolinly and phthalimido, each of said group may be substituted by C_{1-3} alkyl, benzyl or phenyl and
(xi) 5- to 6-membered heterocyclic group selected from the group consisting of pydinyl, imidazolyl, indolyl and tetrazolyl,
, and each of said group (d) and (e) may have 1 to 4 substituents selected from the group consisting of
(i) carboxyl which may be esterified by C_{1-4} alkyl,
(ii) phosphono which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyloxy-C_{1-6} alkyl,
(iii) sulfo,
(iv) C_{1-4} alkylsulfonyl, C_{6-10} arylsulfonyl or C_{6-10} aryl-C_{1-4} alkylsulfonyl,
(v) sulfonamido which may be substituted by C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,
(vi) C_{1-3} alkyl group which may be substituted by carboxyl group optionally esterified with C_{1-4}

alkyl, phosphono which may be mono- or di-substituted by C_{1-6} alkyl, sulfo, sulfonamido which may be substituted by C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl and

(v) halogen,

(2) a heterocyclic group selected from the group consisting of tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl,

(3) an acyl group selected from the group consisting of

(i) C_{2-7} alkanoyl which may be substituted by 1 to 2 halogen atoms,

(ii) C_{6-10} arylsulfonyl,

(iii) C_{1-4} alkylsulfonyl, and

(iv) C_{6-10} aryl-C_{1-4} alkylsulfonyl,

each of said group (ii), (iii) and (iv) may have 1 to 4 substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} alkoxy and halogen,

or R_2 and R_3 together with adjacent nitrogen form a 5- or 6- membered cyclic amino selected from the group consisting of piperazinyl, piperidyl, pyrrolidinyl, 2-oxo-piperazinyl, 2,6-dioxopiperazinyl, morpholinyl and thiomorpholinyl, each of said group may have 1 to 4 substituents selected from the group consisting of

(A) hydroxyl which may be substituted with C_{1-3} alkyl or C_{2-7} alkanoyl,

(B) carboxyl which may be substituted with C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(C) phosphono which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyloxy-C_{1-6} alkyl,

(D) sulfo,

(E) sulfonamido which may be substituted with C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(F) C_{1-6} alkyl or C_{2-5} alkenyl which may be substituted by

(i) carboxyl group which may be esterified with C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(ii) phosphono group which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyloxy-C_{1-6} alkyl,

(iii) sulfo group,

(iv) sulfonamido which may be substituted by C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(v) hydroxyl group which may be alkylated with C_{1-3} alkyl or C_{2-7} alkanoyl,

(vi) sulfhydryl group which may be alkylated with C_{1-3} alkyl,

(vii) carbamoyl,

(viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, halogen, aminosulfonyl and amino which may be substituted with C_{1-3} alkyl and

(ix) amino which may be mono- or di-substituted by C_{1-3} alkyl, or

(x) tetrazolyl,

(G) amino which may be mono- or di-substituted with C_{1-3} alkyl,

(H) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl,

(I) cyano,

(J) carbamoyl,

(K) oxo,

(L) heterocyclic group selected from tetrazolyl and

2,5-dihydro-5-oxo-1,2,4-oxazolyl,

(M) carbamoyl substituted with C_{1-4} alkylsulfonyl, C_{6-10} arylsulfonyl or C_{6-10} aryl-C_{1-4} alkylsulfonyl,

(N) sulfhydryl which may be alkylated with C_{1-3} alkyl and

(O) phenyl which may have 1 to 5 substituents selected from hydroxyl, halogen, aminosulfonyl and amino which may be substituted with C_{1-3} alkyl.

9. The compound as claimed in claim 7, wherein R_2 and R_3 together with the adjacent nitrogen of the carbamoyl form a 5 to 6-membered ring selected from the group consisting of 1-piperazinyl, piperidino, 1-pyrrolidinyl, 2-oxo-1-piperazinyl and 2,6-dioxo-1-piperazinyl, each of the said group may have 1 to 2 substituents of C_{1-6} alkyl which may be substituted by

(i) carboxyl which may be esterified with C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(ii) phosphono group which may be mono- or di-substituted by C_{1-6} alkyl or C_{2-7} alkanoyl-C_{1-6} alkyl,

(iii) sulfo group,

(iv) sulfonamido which may be substituted by C_{1-6} alkyl or C_{6-10} aryl-C_{1-4} alkyl,

(v) hydroxyl group which may be alkylated by C_{1-3} alkyl,

(vi) sulfhydryl which may be alkylated by C_{1-3} alkyl,

(vii) carbamoyl,

(viii) phenyl which may have 1 to 5 substituents selected from the group consisting of hydroxy, halogen, aminosulfonyl and amino which may be substituted with C_{1-3} alkyl,

(ix) amino which may be mono- or di-substituted by C_{1-3} alkyl, or

(x) tetrazolyl.

10. The compound as claimed in claim 7, wherein R_2 is hydrog n or C_{1-7} alkyl and R_3 is C_{1-4} alkylsulfonyl.

11. The compound as claimed in claim 1, wherein the heterocyclic group represented by X is tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl, or 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl.

12. The compound as claimed in claim 1, wherein
R_1 is methyl, W is chlorine atom,
R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group represented by the formula



wherein R_2' is hydrogen or C_{1-7} alkyl and R_3' is C_{1-4} alkyl.

13. The compound as claimed in claim 1, wherein
R_1 is methyl, W is chlorine atom,
R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group repres nted by th formula



wherein R' is hydrogen or C_{1-7} alkyl and n is an integer from 1 to 5.

14. The compound as claimed in claim 1, wherein R_1 is methyl, W is chlorine atom, R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is a carbamoyl group represented by the formula



wherein R" is hydrogen or C_{1-4} alkyl.

15. The compound as claimed in claim 1, wherein R_1 is methyl, W is chlorine atom, R is C_{3-6} branched alkyl which has 1 to 3 substituents selected from the group consisting of hydroxyl, acetyloxy, propionyloxy, t-butoxycarbonyloxy, palmitoyloxy, dimethylaminoacetyloxy and 2-aminopropionyloxy, and X is tetrazolyl.

16. The compound as claimed in claim 1, which is (3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide, (3R,5S)-N-methanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamid , (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-m thylpropyl)-2-oxo-N-[2-(pyrrolidin-

1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzazepine-3-acetamide,
or a salt thereof.

17. The compound as claimed in claim 1, which is
(3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
(3R,5S)-N-methanesulfonyl-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide,
N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid,
N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester,
N-[(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid ethyl ester or a salt thereof.

18. The compound as claimed in claim 1, which is
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2-hydroxymethyl-2-methylpropyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-t trazol-5-yl]methyl-4,1-benzoxazepine-3-

one,
(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one,
(3R,5S)-1-(3-acetoxy-2-acetoxymethyl-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-3-[1H(or 3H)-tetrazol-5-yl]methyl-4,1-benzoxazepine-3-one or a salt thereof.

19. The compound as claimed in claim 1, which is (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-N-[2-(pyrrolidin-1-yl)ethyl]-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide or a salt thereof.

20. The compound as claimed in claim 1, wherein
R is a lower alkyl group which may be substituted with one or two hydroxyl groups,
X is carbamoyl group, which may have substituent(s) on the nitrogen atom of the carbamoyl group,
said substituent being
(1) hydrocarbon selected from the group consisting of
(a) C_{1-7} alkyl,
(b) C_{3-7} cycloaklyl,
(c) C_{2-6} alkenyl,
(d) C_{6-10} aryl and
(e) C_{7-14} arylalkyl,
wherein each of said groups (a), (b) and (c) may have 1 to 4 substituents selected from the group consisting of
(i) carboxyl which may be esterified with C_{1-6} alkyl or C_{7-10} arylalkyl,
(ii) phosphono group,
(iii) sulfo group,
(iv) sulfonamido which may be substituted by C_{1-6} alkyl or C_{7-10} arylalkyl,
(v) hydroxyl group which may be alkylated with C_{1-3} alkyl,
(vi) sulfhydryl group which may be alkylated with

C_{1-3} alkyl,

(vii) carbamoyl,

(viii) phenyl which may have substituent(s) selected from the group consisting of hydroxyl, chlorine, fluorine, aminosulfonyl and amino which may be mono or di-substituted by C_{1-3} alkyl,

(ix) amino which may be mono- or di-substituted by C_{1-3} alkyl,

(x) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl, each of said group may be substituted by C_{1-3} alkyl, benzyl or phenyl and

(xi) 5- to 6-membered heterocyclic group selected from the group consisting of pyridinyl, imidazolyl, indolyl and tetrazolyl,

, and each of said group (d) and (e) may have 1 to 4 substituents selected from the group consisting of

(i) carboxyl which may be esterified by C_{1-4} alkyl,

(ii) phosphono,

(iii) sulfo,

(iv) sulfonamido which may be substituted by C_{1-6} alkyl or C_{7-10} arylalkyl,

(v) C_{1-3} alkyl group which may be substituted by carboxyl group optionally esterified with C_{1-4} alkyl, phosphono, sulfo, or sulfonamido optionally substituted with C_{1-6} alkyl or C_{7-10} arylalkyl, and

(vi) halogen.

(2) a heterocyclic group selected from the group consisting of tetrazolyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazolyl, 4,5-dihydro-5-thioxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-oxadiazolyl, 2,3-dihydro-3-thioxo-1,2,4-oxadiazolyl, 3,5-dioxo-1,2,4-oxadiazolidinyl, 4,5-dihydro-5-oxo-isoxazolyl, 4,5-

dihydro-5-thioxo-isoxazolyl, 2,3-dihydro-2-oxo-1,3,4-oxadiazolyl, 2,3-dihydro-3-oxo-1,2,4-tetrazolyl and 2,3-dihydro-3-thioxo-1,2,4-tetrazolyl,

(3) an acyl group selected from the group consisting of

(i) C_{2-7} alkanoyl which may be substituted by 1 to 2 halogen atoms,

(ii) C_{6-10} arylsulfonyl,

(iii) C_{1-4} alkylsulfonyl, and

(iv) C_{7-14} arylalkylsulfonyl,

each of said group (ii), (iii) and (iv) may have 1 to 4 substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} alkoxy and halogen or

(4) cyclic amino carbonyl group, the cyclic amino group being selected from the group consisting of piperazinyl, piperidyl, pyrrolidinyl, 2-oxo-piperazinyl, 2,6-dioxopiperazinyl, morpholinyl and thiomorpholinyl, each of said group may have 1 to 4 substituents selected from the group consisting of

(i) hydroxyl,

(ii) carboxyl optionally esterified with C_{1-4} alkyl,

(iii) phosphono,

(iv) sulfo,

(v) sulfonamido optionally substituted with C_{1-6} alkyl or C_{7-10} arylalkyl,

(vi) C_{1-3} alkyl or C_{2-5} alkenyl optionally substituted with (i), (ii), (iii), (iv) or (v) defined above,

(vii) amino optionally mono- or di-substituted with C_{1-3} alkyl,

(viii) cyclic amino group selected from the group consisting of piperidyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, 4-methylpiperazinyl, 4-benzylpiperazinyl and 4-phenylpiperazinyl,

(ix) cyano,

(x) carbamoyl,
(xi) oxo,
(xii) C_{1-3} alkoxy,
(xiii) heterocyclic group selected from tetrazolyl and 2,5-dihydro-5-oxo-1,2,4-oxazolyl, and
(xiv) carbamoyl substituted with C_{6-10} arylsulfonyl, C_{1-4} alkylsulfonyl or C_{7-14} arylalkylsulfonyl.

21. A composition which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition for inhibiting squalene synthetase, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition for lowering the level of triglyceride, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition for lowering the lipid-level, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition for prophylaxis or therapy of hyperlipidaemia, which comprises the compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

26. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition.

27. Use of the compound as claimed in claim 1 for manufacturing a squalene synthetase inhibitor.

28. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition for lowering the level of triglyceride.

29. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition for lowering the lipid-level.

30. Use of the compound as claimed in claim 1 for manufacturing a pharmaceutical composition for prophylaxis or therapy of hyperlipidaemia or coronary sclerosis.

31. A method for inhibiting squalene synthetase in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

32. A method for lowering the level of triglyceride in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

33. A method for lowering the lipid-level in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

34. A method for prophylaxis or therapy of hyperlipidaemia or coronary sclerosis in a mammal comprising administering an effective amount of the compound as claimed in claim 1 to said mammal.

35. A process for producing the compound as claimed in claim 1, wherein X is an optionally substituted carbamoyl group, which comprises reacting a compound of the formula:



wherein the symbols are as defined in claim 1, or a salt thereof with a compound of the formula:



wherein the symbols are as d fined in claim 7, or a salt thereof.

36. The compound as claim d in claim 1, wherein R is 2,2-dimethyl-3-hydroxypropyl.